Article
This [demographic] shift will have a disproportionate impact on the specialty of ophthalmology.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA
3 Things You Should Know About Interventional Glaucoma Comanagement
NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits
Patient-Centered Treatment Strategies in the Management of nAMD and DME
Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy
Kiora Pharmaceuticals Secures US Patent for KIO-104